Evidence map›Paper›PMID 33493502›Full record

ArticleGastroenterology2021

Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus.

Christopher Douville, Helen R Moinova, Prashanthi N Thota, Nicholas J Shaheen, Prasad G Iyer, Marcia Irene Canto, Jean S Wang, John A Dumot, Ashley Faulx, Kenneth W Kinzler and 6 more

Registry-linked trialOpen access · greenAbstract readValidation Study
In one paragraph

Article in Gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00288119 (Genetic and Environmental Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00288119 recruitingnot on this map

Genetic and Environmental Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

TypeobservationalSponsorCase Western Reserve UniversityRan2005 to 2028Enrolled2,000ConditionsBarrett's Esophagus, Esophageal NeoplasmArmsBalloon Capsule Device, Endoscopy
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Biomarker Use in Barrett's Esophagus Surveillance.The American journal of gastroenterology · 2026
    Review
  3. Diagnostic and Prognostic Biomarkers for Barrett's Esophagus.Gastroenterology clinics of North America · 2026
    Review
  4. Article
  5. Emerging Biomarkers for Managing Barrett's Esophagus.Gastrointestinal endoscopy clinics of North America · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Update on Barrett Esophagus Diagnosis and Management.Gastroenterology & hepatology · 2023
    Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 1 country.

Christopher DouvilleDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Ludwig Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Helen R MoinovaDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio.
Prashanthi N ThotaDepartment of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, Ohio.
Nicholas J ShaheenCenter for Esophageal Diseases and Swallowing, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
Prasad G IyerDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Marcia Irene CantoDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Jean S WangDepartment of Medicine, Washington University in St. Louis, St. Louis, Missouri.
John A DumotDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio.
Ashley FaulxDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio.
Kenneth W KinzlerDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Ludwig Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Nickolas PapadopoulosDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Ludwig Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Bert VogelsteinDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Ludwig Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Sanford D MarkowitzDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio; Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio. Electronic address: sxm10@case.edu.
Chetan BettegowdaDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Ludwig Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Joseph E WillisCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio; Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio; Department of Pathology, Case Western Reserve University, Cleveland, Ohio.
Amitabh ChakDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio; Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio. Electronic address: amitabh.chak@uhhospitals.org.
Johns Hopkins University · USCase Western Reserve University · USUniversity Hospitals of Cleveland · USCleveland Clinic · USHoward Hughes Medical Institute · USMayo Clinic · USUniversity of North Carolina at Chapel Hill · USWashington University in St. Louis · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and PreventionP50CA150964 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2011 to 2022
$24.6M
The Cleveland Digestive Diseases Research Core Center (DDRCC)P30DK097948 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Theresa Torres Pizarro · 2015 to 2026
$15.6M
Whole Exome Approaches for Esophageal Adenocarcinoma Susceptibility GenesU54CA163060 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CHAK, AMITABH, GUDA, KISHORE · 2011 to 2022
$14.0M
Multi-analyte Approach for Earlier Detection of Cancers in Non Plasma BiofluidsU01CA230691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Nishant Agrawal, CHETAN BETTEGOWDA · 2018 to 2026
$6.7M
Identify and validate novel epigenetic molecular markers for colorectal neoplasmU01CA152756 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY, GUDA, KISHORE · 2010 to 2021
$6.7M
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and TreatmentR35CA197442 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2017 to 2023
$6.6M
Minimally Invasive Molecular Approaches for the Detection of Barrett’s Esophagus and Esophageal AdenocarcinomaR01CA241164 · NCI · MAYO CLINIC ROCHESTER · PI Jagpreet Chhatwal, Prasad G. Iyer · 2019 to 2026
$3.9M
Interrogating malignant gliomas using released tumor DNA in cerebrospinal fluidR37CA230400 · NCI · JOHNS HOPKINS UNIVERSITY · PI BETTEGOWDA, CHETAN · 2018 to 2024
$2.6M
Validation of Methylated Vimentin as a Diagnostic Test for Barrett's EsophagusUH3CA205105 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI WILLIS, JOSEPH EDWARD · 2019 to 2020
$653k
NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA150964NCI NIH HHS R01 CA241164NCI NIH HHS R35 CA197442NCI NIH HHS R37 CA230400NCI NIH HHS U01 CA152756NCI NIH HHS U01 CA230691NCI NIH HHS U54 CA163060NCI NIH HHS UH3 CA205105NIDDK NIH HHS P30 DK097948
6 · The paper itself

Abstract

BACKGROUND &

aimsAneuploidy has been proposed as a tool to assess progression in patients with Barrett's esophagus (BE), but has heretofore required multiple biopsies. We assessed whether a single esophageal brushing that widely sampled the esophagus could be combined with massively parallel sequencing to characterize aneuploidy and identify patients with disease progression to dysplasia or cancer.

methodsEsophageal brushings were obtained from patients without BE, with non-dysplastic BE (NDBE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), or adenocarcinoma (EAC). To assess aneuploidy, we used RealSeqS, a technique that uses a single primer pair to interrogate ∼350,000 genome-spanning regions and identify specific chromosome arm alterations. A classifier to distinguish NDBE from EAC was trained on results from 79 patients. An independent validation cohort of 268 subjects was used to test the classifier at distinguishing patients at successive phases of BE progression.

resultsAneuploidy progression was associated with gains of 1q, 12p, and 20q and losses on 9p and 17p. The entire chromosome 8q was often gained in NDBE, whereas focal gain of 8q24 was identified only when there was dysplasia. Among validation subjects, a classifier incorporating these features with a global measure of aneuploidy scored positive in 96% of EAC, 68% of HGD, but only 7% of NDBE.

conclusionsRealSeqS analysis of esophageal brushings provides a practical and sensitive method to determine aneuploidy in BE patients. It identifies specific chromosome changes that occur early in NDBE and others that occur late and mark progression to dysplasia. The clinical implications of this approach can now be tested in prospective trials.

Indexed as

AneuploidyAdenocarcinomaBarrett EsophagusCross-Sectional StudiesCytological TechniquesDisease ProgressionEsophageal NeoplasmsEsophagusHigh-Throughput Nucleotide SequencingHumansAneuploidyBarrett’s EsophagusChromosome 8qRealSeqS

Identifiers

PMID33493502
PMCPMC8141353
OpenAlexW3126113365

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.